VEGF antagonist formulations suitable for intravitreal administration

US12331099B2 · 06/17/2025

FIG. 1 · Sheet 1

Download patent PDF Write about this patent

Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein …

Full text

3 sections

Abstract Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.

Official name

VEGF antagonist formulations suitable for intravitreal administration

Publication number

US12331099B2

Inventor / creator

Eric Furfine

Assignee / owner

Regeneron Pharmaceuticals, Inc.

Filing

10/23/2024

Publication

06/17/2025

Expiry

10/23/2044

Status

ACTIVE

Open Google Patents →

No articles yet — metadata is still available from the registry.

Comments

0 replies · cite patents with ^

Join the discussion

Continue with Google

No comments yet.